The week in industry: First and only gene therapy approved for pediatric patients with SMA
This week: Eli Lilly (IN, USA) set to acquire worldwide rights for non-opioid pain treatment, data shows that the UK is a world leader in vaccine exports and the EMA has accepted a Marketing Authorization Application for a trastuzumab biosimilar.
Please sign in or register for FREE
Sign in to RxNet
Not yet a member? Become a member FREE to:
- Get unlimited access to ALL CONTENT
- Read selected articles from journals such as Future Medicinal Chemistry FREE
- Receive a weekly email roundup of the latest news and expert opinions
Did you know?
Your RxNet account also gives you access to communities on regenerative medicine, real-world evidence and 3D printing in medicine. Find out more>>